- 1Department of Hematology, Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, China
- 2Department of Hematology, The General Hospital of Western Theater Command, Sichuan Clinical Research Center for Hematological Disease, Branch of National Clinical Research Center for Hematological Disease, Chengdu, China
- 3Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China
- 4Shanghai YaKe Biotechnology Ltd., Shanghai, China
A Correction on
Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma
By Zou Z, Lai S, Yi H, Zhang Q, Yao H, Yang H, Zhang L, Chang AH, Su Y and Rao J (2025) Front. Immunol. 16:1570214. doi: 10.3389/fimmu.2025.1570214
File Table 1 was erroneously published with the original version of this paper. The file has now been removed.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: primary central nervous system lymphoma (PCNSL), T-cell lymphoma, cerebellar, ALK, ALCL, CAR-T, CD30, CD7
Citation: Zou Z, Lai S, Yi H, Zhang Q, Yao H, Yang H, Zhang L, Chang AH, Su Y and Rao J (2025) Correction: Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma. Front. Immunol. 16:1674954. doi: 10.3389/fimmu.2025.1674954
Received: 28 July 2025; Accepted: 14 August 2025;
Published: 22 August 2025.
Edited and reviewed by:
Avichai Shimoni, Sheba Medical Center, IsraelCopyright © 2025 Zou, Lai, Yi, Zhang, Yao, Yang, Zhang, Chang, Su and Rao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alex H. Chang, Y2hhbmdhaEB5YWtlYmlvdGVjaC5jb20=; Yi Su, c3VoYW5nMTIzNEBob3RtYWlsLmNvbQ==; Jin Rao, cmFvamluNzIwMzI1QDE2My5jb20=
†These authors have contributed equally to this work